The sequential expression of CD19 and BCMA in MM tumor cell development suggests that targeting the two biomarkers simultaneously with CART could be a practical strategy to achieve a more efficient response against MM. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.